biomedical research: a perspective from washington, dc

19
Jennifer Zeitzer, Director of Legislative Relations Office of Public Affairs SfG/ASMB Joint Meeting, Nov, 14, 2012 Biomedical Research: A Perspective from Washington, DC

Upload: elda

Post on 23-Feb-2016

43 views

Category:

Documents


0 download

DESCRIPTION

Biomedical Research: A Perspective from Washington, DC. Jennifer Zeitzer , Director of Legislative Relations Office of Public Affairs. What is FASEB? . What Does FASEB Do?. Our Mission… - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Biomedical Research:  A Perspective from Washington, DC

Jennifer Zeitzer, Director of Legislative RelationsOffice of Public Affairs

SfG/ASMB Joint Meeting, Nov, 14, 2012

Biomedical Research: A Perspective from Washington, DC

Page 2: Biomedical Research:  A Perspective from Washington, DC

What is FASEB?

Page 3: Biomedical Research:  A Perspective from Washington, DC

What Does FASEB Do?

Our Mission… Advance health and welfare by promoting

progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.

It is accomplished through FASEB Public Affairs activities including… Policy research and development Advocacy and our role as government liaison Coalition building Communication and outreach

Page 4: Biomedical Research:  A Perspective from Washington, DC

Core Science Policy IssuesFASEB policy development, advocacy, coalition-building,

and communication frequently revolves around these issues…

TRANSLATIONALBASIC

Research Portfolio Balance

Animals in Research

Stem Cell Research

Annual Funding for NIH, NSF, DOE,

USDA, VA

Training and Workforce

Regulatory Burden Peer Review Open Access

Biosecurity

Page 5: Biomedical Research:  A Perspective from Washington, DC

A Day In The Life…Direct lobbying/advocacy

Meetings with members of Congress & their staff

Information gathering Attend Congressional hearings and

agency briefings Monitor news, federal legislation

progress, regulatory agency policies, scientific advances

Writing & reporting Washington Update newsletter Press releases Policy summaries and analysis FASEB statements, testimony, letters,

talking points, and press releases

Page 6: Biomedical Research:  A Perspective from Washington, DC

2012 Election Results

www.faseb.org

Senate54 – 45 – 1*

D R I

* Sen. Elect Angus King (ME) is an Independent.He is expected to caucus with the Democrats.

Dems +2

Republicans -2

197 – 233 D R

House

5 House Races Are Undecided (as of 11.12.2012)

AZ-02: Ron Barber (D) ahead by 700 votesCA-07: Recount likelyCA-52: Recount likelyFL-18: Patrick Murphy (D) ahead by 1,900 votes. Allen West (R) has not concededNC 7: Recount in process

Page 7: Biomedical Research:  A Perspective from Washington, DC

Changes in Key Committees

www.faseb.org

Daniel Inouye (D-HI), ChairmanRichard Shelby (R-AL), Ranking Member

Patty Murray (D-WA), ChairmanJeff Sessions (R-AL), Ranking Member

Tom Harkin (D-IA), ChairmanMike Enzi (R-WY), Ranking Member

Hal Rogers (R-KY), ChairmanNita Lowey (D-NY), Ranking Member

Paul Ryan (R-WI), ChairmanChris Van Hollen (D-MD), Ranking Member

Fred Upton (R-MI), ChairmanHenry Waxman (D-CA), Ranking Member

Changes noted in italics

Page 8: Biomedical Research:  A Perspective from Washington, DC

Potential New Congressional Champions

Senator-Elect Tammy Baldwin (D-WI)

Senator-Elect Tim Kaine (D-VA)

Representative-Elect Bill Foster (D-IL-11)

Representative-Elect Joe Kennedy (D-MA-04)

Representative-Elect Mark Pocan (D-WI-02)

Representative-Elect Scott Peters (D-CA-52)

www.faseb.org

Page 9: Biomedical Research:  A Perspective from Washington, DC

www.faseb.org

Page 10: Biomedical Research:  A Perspective from Washington, DC

Agenda for the “Lame Duck” SessionCongress is back to work on Capitol Hill but will break

for Thanksgiving Nov. 19 – 23, leaving only 4 weeks before Christmas to tackle a MASSIVE “To Do” list:

Farm Bill Medicare payment rates for doctors Expiration of the Bush era tax cuts Alternative minimum tax Tax “extenders” (e.g. R & D tax credit) Unfinished Fiscal Year 2013 spending bills Sequestration Raising the debt ceiling Supplemental disaster aid for Hurricane Sandy Extension of Social Security payroll tax holiday Extension of unemployment benefits Cybersecurity legislation

www.faseb.org

Page 11: Biomedical Research:  A Perspective from Washington, DC

Fiscal Year 2013 Science Funding Current Funding

(As of Nov. 1)

House Recommended

Senate Recommended

NIH $30.6 billion $30.6 billion(flat funding)

$30.7 billion(+$100 million / +0.3%)

NSF $7.0 billion $7.3 billion(+$299 million

/+4.3%)

$7.2 billion(+$240 million / +3.4%)

www.faseb.org

Fiscal year 2013 began on Oct. 1, 2012. However, since Congress did not pass any of the 2013 funding bills, all federal agencies are

currently operating under a “continuing resolution” (H J Res 117) that expires on March 27, 2013.

Page 12: Biomedical Research:  A Perspective from Washington, DC

Super Committee fails to agree on plan to reduce deficit by $1.5

trillion

Congress adopts plan to cut deficit

by $1.5 trillion

UNLIKELY

Congress passes bill to

cancel sequestration SEQUESTRATION

8% - 10% cut to non-defense discretionary

spending (NIH, NSF, etc.)

November 2011

January – December 2012

Obama vetoes the bill?

“Sequestration”

OR

Jan. 2, 2013

Page 13: Biomedical Research:  A Perspective from Washington, DC

Sequestration: Impact on Science Funding NIH, NSF, and other agencies face at least an 8%-10% cut. However, several

programs* will be exempt from sequestration – so NIH and NSF will have to absorb more of the cuts

In April FASEB released an analysis illustrating the potential damage to NIH if sequestration is implemented

11.1% ($2.8 billion) cut to the FY 2013 extramural budget Loss of 700 (OMB estimate) to 2,300 grants (NIH/ Senator Harkin, D-IA, estimate) FASEB estimates that the NIH cuts will exceed $100 million in 8 states (CA/ MD/

MA/ NY/ NC/ PA/ TX/ WA) FASEB has factsheets showing impact of sequestration on NIH funding for each

state

NSF could face a cut of $530 million Loss of 1,500 research & education grants

* Exempted from sequestration: Veterans medical care, Pell grants, salaries/benefits for members of the military, etc.

Page 14: Biomedical Research:  A Perspective from Washington, DC

Sequestration Scenarios

Five Options Have Emerged….

1. Jump Off the Fiscal Cliff

2. Strike A “Grand Bargin”

3. Balanced Approach

4. Kick-the-Can (No Deficit Reduction)

5. Kick-the-Can + Down Payment on Deficit Reduction

www.faseb.org

Page 15: Biomedical Research:  A Perspective from Washington, DC

The Scenarios And Funding For Research

1. Jumping Off the Cliff = 8% - 10% cut for NIH

2. “Grand Bargin” = focus would be on tax code changes and cuts to entitlements, potentially limiting cuts to research and other programs

3. Balanced Approach = the best option, especially if it includes no further cuts to research and other programs

4. Kick-the-Can/ No Deficit Reduction = not likely given the possibility of another downgrade to the U.S. credit rating

5. Kick-the-Can/ Down Payment on Deficit Reduction = almost as bad as Scenario #1 because the “down payment” would include cuts to research and other programs

www.faseb.org

Page 16: Biomedical Research:  A Perspective from Washington, DC

How YOU Can Get Involved

Subscribe to FASEB’s Washington Update

Follow us on Twitter - @FASEBopa Become a fan of our Facebook page Explore FASEB’s NIH and NSF

Advocacy Clearinghouses Join one of the 26 FASEB member

societies for extensive benefits!

Let FASEB help you get started!

Page 17: Biomedical Research:  A Perspective from Washington, DC

Promote The Benefits of Research!Scientists can do a lot to engage policymakers

and the public:Tell a

personal story

Invite your

members of

Congress to your

lab

Speak to a

community group

Go to Capitol

Hill

Write a letter to

the newspap

erVisit

members of Congress in your home

state

Page 18: Biomedical Research:  A Perspective from Washington, DC

www.faseb.org

FASEB Advocacy Resources

Visit our Congressional Visit Toolbox

Sign Up for our E-Action Alerts

Page 19: Biomedical Research:  A Perspective from Washington, DC

www.faseb.org

FASEB Office of Public Affairshttp://www.faseb.org/Policy-and-Government-Affairs.aspx

Jennifer ZeitzerDirector of Legislative Relations

[email protected] (301) 634-7128

For More Information